Project description
Innovative diagnostic device for breast cancer screening
Breast cancer is one of the leading causes of cancer-related deaths. While the chance of survival significantly increases with early detection, the current mammography technique fails to detect half of the cancers in cases with dense breast tissue. Unfortunately, this high-risk group is also the group for which mammography is least effective. The United Kingdom company Tiro Medical has developed a breast imaging device that uses optical elastography and digital physiological analysis. The device imaging has a higher contrast ratio in dense tissues and improved diagnosis in the target population without the use of radiation. The EU-funded project will re-evaluate the product specification based on the user requirements and build the development plan, including market analysis.
Objective
Tiro Medical was formed in 2014 by a multidisciplinary shareholder group, including academic and healthcare organisations along with clinical and industry experts. Tiro Medical develops tools for the Digital Medicine sector, creating products that enhance the diagnostic and treatment decision making processes, improving the standard of care whilst reducing expenditure.
Breast cancer is the second leading cause of cancer-related death in women there are 1.7 million new cases of breast cancer occur each year, with a global economic burden estimated at US$88 billion. A woman's chance of survival is significantly increased with early detection. The mammography technique has major limitations and fails to detect approximately half of cancers in women with dense breast tissue. Women with dense breast tissue have a 4 to 6 times increased risk of breast cancer compared to women with non-dense tissue. Unfortunately the group at highest risk of cancer is also the group for which mammography is least effective.
Tiro Medical have developed a breast imaging device (the OE scan) based on the use of Optical Elastography and Digital Physiological Analysis. The Tiro solution has higher contrast ratio in dense tissues allowing for improved diagnosis in this population, uses zero radiation so is not limited by age and can be used at any age and in any condition (pregnancy, specific illness etc.) and has zero pain leading to better compliance. The company is currently in talks with potential stakeholder companies in the EU who have shown an active interest in the project.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicineoncologybreast cancer
- medical and health sciencesclinical medicineobstetrics
- engineering and technologymedical engineeringdiagnostic imaging
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
SE1 0BL LONDON
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.